Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has successfully completed the allotment of over 67 million shares at $0.115 each, raising $13 million through an institutional placement. This capital raise bolsters Amplia’s financial position as it continues its research and trials, particularly in developing its promising cancer drug, narmafotinib. The company’s strategic focus on FAK inhibitors positions it attractively in the evolving cancer treatment market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
